AstraZeneca
Q4 and Full Year 2014 Results
Cautionary statement regarding forward-looking
statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the
following cautionary statement:
This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group.
Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.
The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes
no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes',
'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained
in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing
exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and
insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that
strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of
substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk
of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing
regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting
business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned
cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could
have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery
and anti-corruption legislation.
Nothing in this presentation should be construed as a profit forecast.
2
Q4 and Full Year 2014 Results
Pascal Soriot
Overview
Luke Miels
Growth platforms
Marc Dunoyer
Finance
Briggs Morrison
Pipeline
Pascal Soriot
Closing
3
2014: Continued strategic progress
Returning to growth
•  Q4 2014: 4th consecutive quarter of revenue growth; $6,683m, +2% (+3% excl. effect of US Branded Pharma Fee)
•  FY 2014: Growth platforms +15%; 53% of total revenue:
•  Brilinta: +70%
•  Diabetes: +139%
•  Respiratory: +10%
•  Emerging Markets: +12%; China +22%
•  Japan: -3%
Achieving scientific leadership
•  Since Q3 2014:
•  Duaklir Genuair: Approval EU; lesinurad: Regulatory submission US, EU; brodalumab: Positive Phase IIIs
•  Saxa/dapa: Regulatory submission US; Brilinta: Positive PEGASUS Phase III
•  Lynparza: Approval US, EU; Iressa: Regulatory submission US
•  Moventig: Approval EU
Growth rates at constant exchange rates (CER)
4
2014: Upgraded guidance fully met
FY 2014
$m
Revenue
26,095
3
Growth platforms
13,928
15
US
10,120
4
Europe
6,638
(1)
Emerging Markets
5,827
12
2,242
22
Japan
2,227
(3)
Core EPS
$4.28
(8)
China
5
CER
growth %
Strategic priorities
Achieve
scientific
leadership
6
1
Return
to growth
2
3
Be a great
place to work
Achieve scientific leadership
Industry-leading number of
NDA/BLA approvals in 2014
On track to deliver 7-8 potential
NME submissions in 2015-2016
CAZ AVI (CEPH/BLI)
serious infections
Additional approvals
Duaklir Genuair
cediranib (VEGFR)
ovarian cancer (EU)
AZD6094 (MET)
papillary renal cell carcinoma
selumetinib (MEK)
uveal melanoma
tremelimumab (CTLA-4)
mesothelioma
AZD9291 (EGFR)
2L NSCLC
MEDI4736 (PD-L1)
3L NSCLC
brodalumab* (IL-17R)
psoriasis
roxadustat (HIF)
CKD / ESRD (China)
PT003 (LAMA/LABA)
COPD
benralizumab (IL-5R)
severe asthma
2015
* Partner Amgen to manage regulatory submission
7
2016
Evolving the business model to create maximum value
from strong R&D productivity
Biotechs
Out-license
Externalisation
Partner
Internal
development
Development
Manufacturing
Commercialisation
Value creation through Internal development and Externalisation
8
Return to growth: Strong development of growth platforms
Growth platforms
(% of revenue)
Total revenue
(% change vs. 2013)
Revenue
$m
Revenue
$m
53%
14,000
12,000
49%
41%
10,000
5,000
8,000
4,000
6,000
3,000
4,000
2,000
2,000
1,000
FY 2012
+3%
+4%
+5%
+2% (+3%*)
Q1 2014
Q2 2014
Q3 2014
Q4 2014
6,000
0
FY 2013
FY 2014
Growth rates at constant exchange rates (CER) *Excluding effect of US Branded Pharmaceutical Fee
9
7,000
0
Growth platforms
Luke Miels, EVP Global Portfolio & Product Strategy
Growth platforms: Strong delivery
FY 2014
Brilinta
$476m
70%
Diabetes
$1,870m
139%
Respiratory
$5,063m
10%
Emerging Markets
$5,827m
12%
Japan
$2,227m
-3%*
Oncology emerging as sixth growth platform
Growth rates at constant exchange rates (CER) *Including impact from mandated price cuts
11
Growth
Brilinta: Continued progress
$m
•  Q4 2014 revenue +52% to $133m
140
EM
$21m
120
EST ROW
$9m
100
80
EUR
$60m
60
40
US
$43m
20
0
Q4 2013
•  US +79% to $43m supported by positive
news flow from DoJ closure and NSTE-ACS*
guideline changes in October
•  Continued growth in Europe; Emerging
Markets more than doubling sales
•  PEGASUS-TIMI 54 study positive:
Significant reduction in major CV events in
patients with history of heart attack
Q4 2014
Growth rates at constant exchange rates (CER) *NSTE-ACS = Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes
12
Brilinta: Steady increase in US
US oral anti-platelet class market shares
(new-to-brand prescriptions NBRx)
US hospital units purchased
60,000
15%
49,960
2013
50,000
40,000
40,314
2014
10%
8.07%
30,000
7.57%
20,000
5%
Brilinta
Competitor
Source: IMS Health DDD (Defined Daily Dose) weekly (MMT: 4 week rolling average) through w/e Jan 9, 2015
13
Source: IMS Health NPA Weekly through w/e Jan 16, 2015
Competitor
05-Jan-15
05-Dec-14
05-Nov-14
05-Oct-14
05-Sep-14
05-Aug-14
05-Jul-14
05-Jun-14
05-Apr-14
Brilinta
05-May-14
05-Jan-14
05-Feb-14
05-Mar-14
05-Dec-13
05-Nov-13
05-Oct-13
05-Sep-13
05-Jul-13
26-Dec-14
5-Dec-14
14-Nov-14
24-Oct-14
3-Oct-14
12-Sep-14
22-Aug-14
1-Aug-14
11-Jul-14
20-Jun-14
30-May-14
9-May-14
18-Apr-14
7-Mar-14
28-Mar-14
14-Feb-14
24-Jan-14
0%
3-Jan-14
0
05-Aug-13
Closure of DoJ
Investigation
10,000
Brilinta: And steady increase globally
2013-2014 ACS
hospital discharge change
Oral anti-platelet market share
(retail + hospital)
8.0%
7%
US
UK
7.0%
6.0%
5%
12%
Spain
5.0%
4.0%
Italy
Germany
3%
3.0%
2.0%
-5%
1.0%
4%
France
0.0%
-10%
-5%
0%
Source: AstraZeneca commissioned Hospital Discharge Tracker, IMS
14
0
4%
Australia
5%
10%
15%
4
8
12
16
20
24
28
32
36
Australia
France
Germany
Spain
UK
US
Source: IMS MIDAS. Spain retail only
Month 1 = month of 1st external sales data for product (does not reflect commercial launch timing)
40
44
Italy
48
Diabetes: Farxiga/Forxiga launch ongoing; encouraging
US Bydureon Pen uptake
$m
500
Others
$103m
400
Bydureon
$123m
300
200
Byetta
$69m
•  Onglyza US demand slightly negative.
High-20s% market share in China
100
Onglyza
$200m
•  Bydureon US fuelled by strong launch of Pen
device. EU launch of Pen starting soon
0
Q4 2013
Growth rates at constant exchange rates (CER) Source: IMS
15
•  Good Farxiga uptake in US, accelerating
SGLT-2 class growth post launch. Strong
Forxiga start in key emerging markets
Q4 2014
Farxiga: Continued US uptake; SGLT-2 market acceleration
post launch
US Farxiga volume
(weekly prescriptions)
US SGLT-2 market
(new monthly prescriptions NRx)
200,000
30,000
27,039
25,000
180,000
Farxiga launch –
driving class growth
160,000
140,000
20,000
120,000
100,000
15,000
80,000
10,000
10,560
5,000
4,317
40,000
NRx
09-Jan-15
19-Dec-14
28-Nov-14
07-Nov-14
17-Oct-14
26-Sep-14
05-Sep-14
15-Aug-14
25-Jul-14
04-Jul-14
13-Jun-14
23-May-14
02-May-14
11-Apr-14
21-Mar-14
28-Feb-14
TRx
Apr-13
May-13
Jun-13
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-14
Jul-14
Aug-14
Sep-14
Oct-14
Nov-14
Dec-14
20,000
0
07-Feb-14
0
60,000
NBRx
Source: TRx and NRX-NPA+7 (Retail, Mail & LTC), NBRx- IMS APLD (Retail and Mail) and IMS Health NPA, weekly through Jan 16, 2015. Monthly data through December, 2014
16
Forxiga: Strong start in key international markets
Farxiga/Forxiga launch uptake among innovative oral anti-diabetic medicines
(SGLT-2 + DPP4)
Market share days on therapy
13
12
11
10
9
8
7
6
5
4
3
2
1
0
M1
M2
M3
M4
USA
Germany
Source: IMS Midas Nov 2014
17
M5
M6
Brazil
UK
M7
M8
Mexico
Australia
M9
M10
Argentina
Norway
M11
M12
Sweden
Chile
M13
M14
M15
Philippines
South Korea
M16
M17
Gulf
M18
M19
M20
Bydureon: Strong US uptake of new Pen; EU launch next
US Bydureon family
(new monthly prescriptions NRx)
US Bydureon family share in GLP-1 market
TRx
NRx
40,000
NBRx
8.5% 5,000
-
Dec-14
3.7% Nov-14
9.5% Oct-14
NBRx
10,000
Sep-14
4.1% Aug-14
3.5% 1.0% Jul-14
0.5% 2.2% Jun-14
0.9% NRx
15,000
May-14
TRx
Source: TRx and NRX-NPA+ (Retail, Mail & LTC), NBRx- IMS APLD (Retail & Mail Combined) Dec
18
Chg Vs
Dec ‘13
May-13
Jun-13
Jul-13
Aug-13
Sep-13
Oct-13
Nov-13
Dec-13
Jan-14
Feb-14
Mar-14
Apr-14
May-14
Jun-14
Jul-14
Aug-14
Sep-14
Oct-14
Nov-14
Dec-14
0%
Chg vs
Sep
Apr-14
Chg Pen
Launch
15%
20,000
Mar-14
20.7%
Feb-14
20%
25,000
Jan-14
20.9%
Dec-13
25%
30,000
Nov-13
33.0%
30%
5%
Bydureon Pen
35,000
35%
10%
Bydureon Tray
Oct-13
40%
Symbicort: US sales growth decelerating; Emerging
Markets strengthening
$m
1,000
900
800
EST ROW
$121m
•  US +13%, decelerating (including impact
from Branded Pharmaceutical Fee)
EUR
$347m
•  EU revenue -7%, stable volume, but price
impact from analogues
700
600
500
400
•  Emerging Markets +25%; China +35%
300
US
$395m
200
100
0
Q4 2013
Growth rates at constant exchange rates (CER)
19
•  Q4 2014 revenue +5% to $978m
EM
$115m
Q4 2014
•  2015: Expect further competitive pressure in
EU & US; very strong growth in Emerging
Markets, including China
Emerging Markets: Continued strong growth
China
13%
Q1 12
23%
20%
21%
Q2 12
Q3 12
Q4 12
Q1 13
Q2 13
Q3 13
23%
21%
Q4 13
Q1 14
Q2 14
2%
Q3 14
9%
5%
3%
2%
19%
Q4 14
12%
5%
0%
-2%
-1%
20
22%
10%
1%
Q1 12
21%
13%
12%
EMs outside China
-3%
21%
Q2 12
+8%
+4%
Q3 12
Q4 12
Q1 13
Q2 13
Q3 13
Q4 13
Q1 14
Q2 14
Q3 14
Q4 14
Japan: Positive underlying demand for growth brands
Overall in-market performance
Key growth brands (2014)
Crestor
36.1% market share (+3.5%-p)
Nexium
22.8% share (+6.6%-p)
Symbicort
$m
35.7% share
(+0.2%-p)
0
In-market growth 4.9% (2014) and 3.2% (Q4)
• 
Reported business sales negatively impacted
by mandated biennial price reductions,
increased use of generics and Nexium recall
in Q4 2014
• 
Continued share growth for Crestor, Nexium
& Symbicort
• 
Q1 2015 last quarter with negative impact
from biennial price reductions
+2%
+38%
+30%
100 200 300 400 500 600
Growth rates at constant exchange rates (CER) Source: IMS Health
21
• 
Launch products
BRCA-mutated advanced ovarian cancer
Opioid-induced constipation
•  US & EU (France 1st) launch in
December 2014
•  Rapid uptake due to bolus of patients
awaiting treatment
•  US launch expected H1 2015
following recent de-scheduling
determination
•  EU launch expected H2 2015
Duaklir
Chronic obstructive pulmonary disease (COPD)
•  EU launch underway
22
Finance
Marc Dunoyer, Chief Financial Officer
2014: Headlines & priorities
2014 headlines
•  Upgraded guidance fully met
•  Continuous investment in R&D to support the accelerating pipeline
•  Investment in growth platforms peaked in Q4 2014
Finance priorities
•  Profit & loss redeployment
•  Balance sheet flexibility
•  Create long-term shareholder value
24
Support progressive dividend
Support return to growth
Support accelerating pipeline
Profit & loss: Redeployment
Core SG&A
32%
Examples
24%
Total IT costs
Total facilities costs
$m
-11%
$m
-8%
G&A
68%
2012
76%
SM&M
2014
Structural change in SG&A due to redeployment
of resources
From fixed to more variable costs
SM&M: Sales, Marketing & Medical
25
2012
2014
2012
2014
Has supported increased investment in:
•  Growth platforms, including Emerging Markets build-up
•  Unprecedented # of on-going/upcoming launches
Balance sheet: Flexibility
Cash conversion cycle (days)
Debt & cash
•  Continue to target a strong, investment-grade
credit rating
Peer average
87
•  Moody’s: A2 Stable outlook
•  Standard & Poor’s: AA- Negative outlook
69
45
•  November 2014: 0.875% EUR 2021 mediumterm notes (€750m); oversubscribed 4 times
•  Cash and cash equivalents end-2014 $6.4bn
•  Net debt $3.2bn
2012
2014
Strategic flexibility to support progressive dividend, return to growth and accelerating pipeline
Cash conversion calculated as DSO + DIO - DPO at the end of the year (in days) as a function of net sales
26
Q4 2014 considerations
Q4
2014
$m
Q4
2013
$m
CER
Growth
%
Factors
Revenue
6,683
6,844
2
+3% excluding US Branded
Pharmaceutical Fee
Core R&D
(1,360)
(1,205)
17
Core SG&A
(2,953)
(2,483)
23
Core
Operating
Profit
R&D investment
•  Pipeline progression/acceleration, e.g.:
• 
• 
• 
Oncology immuno & small molecules
RIA biologics pipeline
Brilinta PARTHENON costs peaked
SG&A
•  Growth platforms; incl. Diabetes
integration
•  On-going launches
–  Farxiga/Forxiga (US, EU, EMs), Bydureon Pen (US)
•  Pre-launch activities
1,184
1,983
(33)
–  Lynparza
–  Movantik/Moventig
•  Almirall integration
Opportunistic investment in Q4 2014
27
2014: Upgraded guidance fully met
FY 2014
$m
CER
growth %
%
sales
Revenue
26,095
25,711
3
Core Gross Profit
21,207
21,078
3
81
(324)
(306)
7
1
(4,941)
(4,269)
15
19
(10,216)
(8,865)
16
39
Core Tax Rate
16%
20%
-
-
Core EPS
4.28
5.05
(8)
Distribution
Core R&D
Core SG&A
28
FY 2013
$m
Accounting for the US Branded Pharmaceutical Fee
•  New regulations in Q3 2014 affecting how the annual branded pharmaceutical
fee is recognised. Affected entities will now accrue for the obligation as each
sale occurs.
•  As the fee is based on actual sales in the current year - we will account for the
fee as a deduction from revenue rather than a charge to SG&A.
•  As a result in 2014, Q4 revenue is reduced by $113m for the second half of
2014. No impact on earnings for the year.
•  Estimated annualised impact as % of revenue: Total US brands (2.2)%,
Symbicort (2.8)%, Nexium (2.4)%, Crestor (2.1%), Brilinta (2.2)%
29
2015 guidance
Sales revenue1
Core EPS
1 Assumes imminent launch of a Nexium generic in the US market
30
Constant
exchange rates
Decline by mid single-digit percent
Increase by low single-digit percent
2015 currency sensitivity
•  The Company also provides the following non-guidance information related to currency sensitivity:
Based on current exchange rates1, sales revenue is expected to decline by low double-digit percent with
Core EPS expected to be broadly in line with 2014.
Currency sensitivity
Impact of 5% weakening in
exchange rate versus USD ($m)1
Average exchange rates versus USD
Currency
Primary relevance
2014
January 20152
EUR
Sales revenue
0.75
0.86
JPY
Sales revenue
105.87
118.44
SEK
Costs
6.86
GBP
Costs
0.61
Change %
Sales revenue
Core operating profit
(12)
(196)
(120)
(11)
(105)
(75)
8.09
(15)
(5)
96
0.66
(8)
(34)
104
(214)
(123)
Other3
1 Based on average daily spot rates in January 2015. 2 Based on 2014 actual group currency exposures. 3 Other important currencies include AUD, BRL, CAD, KRW, RUB.
31
2014: Targeted business development in main areas
Respiratory, Inflammation
NGM
& Autoimmunity
•  Strengthened inhaled portfolio in
asthma and COPD
•  SNG001: Novel, inhaled interferon
beta in clinical development for
severe asthma
Respiratory
TriplePearl
combination
LABA/LAMA/ICS
32
Cardiovascular & Metabolic
Disease
•  Strengthened diabetes portfolio
and commitment to main
therapeutic areas
•  Myalept divestment reinforced
focus on main strategic priorities;
allows for redeployment of
resources
Oncology
•  Strategic partnerships /
acquisitions strengthened
Oncology portfolio, particularly
immuno-oncology-combination
therapies, novel predictive
biomarkers
Respiratory:
Actavis deal strengthens franchise
•  Strategic deal to add US rights to Europe & ROW aclidinium franchise
acquired from Almirall in 2014, including Tudorza (LAMA) and Pressair
DPI device
•  Augments the Respiratory franchise with Actavis product, Daliresp (oral
PDE4 inhibitor for COPD)
•  Access to on-market revenues, near-term growth and future potential
of LAMA combination products
•  Targeted investment in main therapy area: $600m initial consideration
and low single-digit royalties above a certain revenue threshold
Expands geographic presence
Broadens product and device offering
•  Additional $100m payment regarding the settlement of a number of
contractual consents and approvals
Increases focus on the Respiratory growth platform
33
Pipeline
Briggs Morrison, EVP Global Medicines Development
2014: An outstanding year
Outstanding year
•  Industry-leading 6 NDA/BLA approvals
•  Excellent pipeline progress
•  Focusing R&D spend on main therapeutic
areas
35
Improve the lives of 200 million
patients…one patient at a time
2014: Late-stage pipeline highlights
Compound
Indication
Milestone
lesinurad
gout
Phase III topline results; US & EU submission (Q4)
Bydureon Pen
type 2 diabetes
US & EU approval
Farxiga/Forxiga
type 2 diabetes
US & Japan approval
Xigduo
type 2 diabetes
US & EU approval
Epanova
hypertriglyceridaemia
US approval
saxa/dapa FDC
type 2 diabetes
Phase III topline results; US submission (Q4)
Oncology
Lynparza
PSR BRCAm ovarian cancer
US & EU approval (Q4)
Infection
CAZ AVI
serious infections
Phase III topline results
Neuroscience
Movantik/Moventig
opioid-induced constipation
US approval & EU approval (Q4)
RIA
CVMD
FDC = Fixed Dose Combination
36
Recent highlights: Respiratory, Inflammation &
Autoimmunity (RIA)
ACR (November 2014)
Sifalimumab (Phase IIb in lupus/SLE)
•  Key endpoints met
Mavrilimumab (Phase IIb rheumatoid arthritis)
•  Key endpoints met; no apparent safety signals
Lesinurad (Phase III gout)
•  Key endpoints met; comparable AE profile in lesinurad
200mg + allopurinol vs. allopurinol alone
•  Regulatory submissions US, EU (accepted)
37
Symbicort SYGMA study started
•  First Phase III trial for the treatment of mild asthma
•  Potential for improved disease control with flexible asneeded regimen as compared to rescue inhaler
Recent highlights: Cardiovascular & Metabolic Disease
(CVMD)
Diabetes
Saxa/dapa
•  Regulatory submission: US Q4 2014, EU expected
Q2 2015
Farxiga/Forxiga for Type 1 diabetes
•  Phase III programme initiated Q4 2014
Brilinta
•  PEGASUS: Statistically significant reduction in major
CV events in patients with history of heart attack
•  Expect presentation at ACC in March 2015
•  Ongoing PARTHENON programme - SOCRATES
(ischaemic stroke/TIA), EUCLID (PAD), THEMIS (CAD
& T2D)
•  One CV outcomes study each year 2015-2017
Epanova
•  STRENGTH long-term outcomes trial initiated Q4 2014
38
Recent highlights: Oncology
Approvals / Submissions
Latest key milestones
•  Approval US & EU (Q4 2014)
AZD9291 (EGFR)
•  Enrolment complete Phase II (2L NSCLC EGFRm/T790M)
•  First-in-class oral PARP inhibitor approved for the treatment
of gBRCAm advanced ovarian cancer
Tremelimumab (CTLA-4)
•  Enrolment complete Phase II (mesothelioma)
Iressa
MEDI4736 (PD-L1)
•  Completion of Phase I MEDI4736 (PD-L1) / dabrafenib
(BRAF) / trametinib (MEK) (melanoma)
Lynparza
•  US regulatory submission (Q4 2014) for 1L EGFR mutated
NSCLC
•  PDUFA Q3 2015
•  First patient in ARCTIC Phase III (3L NSCLC mono substudy)
•  First patient in ADJUVANT Phase III (adjuvant NSCLC)
MEDI6469 (muOX40)
•  First patient in Phase I (solid tumours; tremelimumab combo
arm)
Immuno-oncology:
13 Phase II or Phase III registration studies
already started or planned to start in 2015
39
Late-stage pipeline: Key news flow through 2015
RIA
CVMD
Oncology
Neuroscience
Compound
Indication
Potential milestone
brodalumab1
psoriasis
Regulatory submission
PT003 (LAMA/LABA)
COPD
Phase III results & regulatory submission
anifrolumab
lupus/SLE
Phase II presentation
lesinurad
gout
Regulatory submission
Brilinta
prior MI (PEGASUS)
Phase III results
saxa/dapa FDC
type 2 diabetes
Regulatory submission
Lynparza
PSR BRCAm ovarian cancer
Approval
Phase III topline results (SOLO-2)
AZD9291
2nd line NSCLC
Regulatory submission
MEDI4736 (PD-L1)
3rd line NSCLC
Phase II/potential registration topline results
MEDI4736 (PD-L1) / tremelimumab
NSCLC
Phase I presentation (ASCO)
cediranib
ovarian cancer
Further analysis (ICON6); EU regulatory submission
selumetinib
uveal melanoma
Phase III results & regulatory submission
Movantik/Moventig
opioid-induced constipation
EU approval, US de-scheduling
US launch
1 Partner Amgen to manage regulatory submission 2 New disclosure since Investor Day November 2014
40
(US)
New2
Oncology: Key milestones through 2015
Expected data presentations 1H 2015
AACR 2015
•  AZD6094 (MET)
Phase I (all comers)
•  AZD8186 (PI3Kb/d)
Phase I (multiple tumour types)
Expected data availability 2015
AZD9291 (EGFR)
•  Phase II (2L NSCLC EGFRm/T790M)
Selumetinib (MEK)
•  Phase III SUMIT (metastatic uveal melanoma)
•  Phase II (paediatric neurofibromatosis-1 [NF-1])
MEDI4736 (PD-L1)
•  Phase II ATLANTIC (3L NSCLC PD-L1+)
ASCO 2015
•  MEDI4736 (PD-L1)
Phase I/II update (NSCLC and SCCHN)
Triplet combination with MEK/BRAF (melanoma)
•  MEDI4736 (PD-L1) +
tremelimumab (CTLA-4)
Phase Ib (NSCLC)
Tremelimumab (CTLA-4)
•  Phase II (mesothelioma)
AZD2014 (TORC)
•  Phase II (ER+ breast doublet & squamous lung)
AZD1775 (Wee1)
•  Phase II (platinum-sensitive ovarian)
AZD6094 (MET)
•  Phase II (papillary renal cell carcinoma)
41
Closing
Pascal Soriot, Chief Executive Officer
Closing remarks
Growth platforms +15% CER, contributing 53% of total revenue
Investments in growth platforms & expanding pipeline
Industry-leading number of NDA/BLA approvals
Pipeline on track to deliver in 2015 and beyond
2015 Core EPS is expected to increase by low single-digit percent at CER
43
Q&A
Pascal Soriot, Chief Executive Officer
Marc Dunoyer, Chief Financial Officer
Briggs Morrison, EVP Global Medicines Development
Luke Miels, EVP Global Portfolio & Product Strategy